|
UA94571C2
(en)
*
|
2004-10-20 |
2011-05-25 |
Мерк Сероно С.А. |
3-arylamino pyridine derivatives
|
|
NZ567140A
(en)
*
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
CA2658725A1
(en)
*
|
2006-08-16 |
2008-02-21 |
Exelixis, Inc. |
Using pi3k and mek modulators in treatments of cancer
|
|
EP2113500A1
(en)
|
2006-10-31 |
2009-11-04 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
CN105106199A
(zh)
|
2006-12-14 |
2015-12-02 |
埃克塞利希斯股份有限公司 |
使用mek抑制剂的方法
|
|
WO2008124085A2
(en)
*
|
2007-04-03 |
2008-10-16 |
Exelixis, Inc. |
Methods of using combinations of mek and jak-2 inhibitors
|
|
CN101679235A
(zh)
*
|
2007-05-10 |
2010-03-24 |
辉瑞有限公司 |
氮杂环丁烷衍生物和它们作为前列腺素e2拮抗剂的用途
|
|
SI2176296T1
(sl)
|
2007-07-16 |
2012-05-31 |
Genentech Inc |
Protitelesa proti CD b in imunokonjugati in postopki za uporabo
|
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
ES2643239T3
(es)
|
2008-01-31 |
2017-11-21 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
|
AU2009225877B2
(en)
|
2008-03-18 |
2014-11-20 |
Genentech, Inc. |
Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US8841462B2
(en)
*
|
2008-07-01 |
2014-09-23 |
Robert A. Heald |
Bicyclic heterocycles as MEK kinase inhibitors
|
|
BRPI0910200A2
(pt)
|
2008-07-01 |
2015-09-29 |
Genentech Inc |
composto, composição farmacêutica, método de inibir o crescimento de células anormais ou de tratar um distúrbio hiperproliferativo em um mamífero e método de tratar uma doença inflamatória em um mamífero
|
|
EP2370568B1
(en)
|
2008-12-10 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
CA2753285A1
(en)
|
2009-03-12 |
2010-09-16 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
|
|
SG175708A1
(en)
|
2009-05-27 |
2011-12-29 |
Genentech Inc |
Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
|
|
SG10201407781SA
(en)
|
2009-09-28 |
2015-01-29 |
Hoffmann La Roche |
Benzoxepin PI3K Inhibitor Compounds And Methods Of Use
|
|
SI2483278T1
(sl)
|
2009-09-28 |
2014-03-31 |
F. Hoffmann-La Roche Ag |
Inhibitorske spojine benzoksazepina pi3k in njihova uporaba pri zdravljenju raka
|
|
MX345155B
(es)
|
2009-10-12 |
2017-01-18 |
F Hoffmann-La Roche Ag * |
Combinaciones de un inhibidor de pi3k y un inhibidor de mek.
|
|
JP5466767B2
(ja)
*
|
2009-11-04 |
2014-04-09 |
ノバルティス アーゲー |
Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
|
|
AR079256A1
(es)
|
2009-12-04 |
2012-01-04 |
Genentech Inc |
Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
|
|
US9073927B2
(en)
|
2010-01-22 |
2015-07-07 |
Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii |
Inhibitors of PI3 kinase
|
|
EP2539337A1
(en)
|
2010-02-22 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
|
RU2571930C2
(ru)
|
2010-02-25 |
2015-12-27 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Мутации braf, обеспечивающие резистентность к ингибиторам braf
|
|
US20130059851A1
(en)
|
2010-03-09 |
2013-03-07 |
Dana-Farber Cancer Institute, Inc. |
Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
|
|
WO2011121317A1
(en)
|
2010-04-01 |
2011-10-06 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
|
|
PH12012501864A1
(en)
|
2010-04-07 |
2017-07-26 |
Hoffmann La Roche |
Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
|
|
WO2011130598A1
(en)
|
2010-04-15 |
2011-10-20 |
Spirogen Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CN110818724B
(zh)
|
2010-05-07 |
2020-11-13 |
吉利德康涅狄格有限公司 |
吡啶酮和氮杂吡啶酮化合物及使用方法
|
|
CA2802808A1
(en)
|
2010-07-14 |
2012-01-19 |
F. Hoffmann-La Roche Ag |
Purine compounds selective for pi3k p110 delta, and methods of use
|
|
WO2012018639A2
(en)
|
2010-07-26 |
2012-02-09 |
Biomatrica, Inc. |
Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
|
|
US9376709B2
(en)
|
2010-07-26 |
2016-06-28 |
Biomatrica, Inc. |
Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
|
|
KR101837223B1
(ko)
|
2010-09-01 |
2018-03-09 |
질레드 코네티컷 인코포레이티드 |
피리디논/피라지논, 그의 제조 방법 및 사용 방법
|
|
US8975260B2
(en)
|
2010-09-01 |
2015-03-10 |
Genetech, Inc |
Pyridazinones, method of making, and method of use thereof
|
|
WO2012052745A1
(en)
|
2010-10-21 |
2012-04-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Combinations of pi3k inhibitors with a second anti -tumor agent
|
|
WO2012068096A2
(en)
|
2010-11-15 |
2012-05-24 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
AU2011343712B2
(en)
|
2010-12-16 |
2015-09-17 |
Genentech, Inc. |
Tricyclic PI3k inhibitor compounds and methods of use
|
|
KR20130116358A
(ko)
|
2011-02-09 |
2013-10-23 |
에프. 호프만-라 로슈 아게 |
Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
|
|
WO2012126901A1
(en)
|
2011-03-21 |
2012-09-27 |
F. Hoffmann-La Roche Ag |
Benzoxazepin compounds selective for pi3k p110 delta and methods of use
|
|
CN102718750B
(zh)
*
|
2011-03-31 |
2015-03-11 |
中国人民解放军军事医学科学院毒物药物研究所 |
含吖啶环的氨基吡啶类衍生物及其用途
|
|
EP2694072B2
(en)
|
2011-04-01 |
2024-08-07 |
Genentech, Inc. |
Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
|
|
CN103841976A
(zh)
|
2011-04-01 |
2014-06-04 |
基因泰克公司 |
Akt和mek抑制剂化合物的组合及其使用方法
|
|
SG11201400681UA
(en)
|
2011-05-19 |
2014-08-28 |
Ct Nac De Investigaciones Oncológicas Cnio |
Macrocyclic compounds as protein kinase inhibitors
|
|
EP2524918A1
(en)
|
2011-05-19 |
2012-11-21 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyrazines derivates as kinase inhibitors
|
|
BR112013030991A2
(pt)
|
2011-06-03 |
2016-11-29 |
Hoffmann La Roche |
uso de gdc-0980 e método de tratamento de mesotelioma
|
|
BR112014002353B1
(pt)
*
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
CN103874700B
(zh)
|
2011-08-12 |
2018-03-30 |
霍夫曼-拉罗奇有限公司 |
吡唑并[3,4‑c]吡啶化合物和使用方法
|
|
AR088061A1
(es)
|
2011-09-27 |
2014-05-07 |
Hoffmann La Roche |
Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
|
|
SG11201401406YA
(en)
|
2011-10-14 |
2014-05-29 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP2776051A4
(en)
*
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
|
BR112014010391A2
(pt)
|
2011-11-03 |
2017-04-18 |
Hoffmann La Roche |
composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
TWI553004B
(zh)
|
2011-11-03 |
2016-10-11 |
建南德克公司 |
８－氟基呔－１（２ｈ）－酮化合物
|
|
PH12014500966A1
(en)
|
2011-11-03 |
2014-06-09 |
Hoffmann La Roche |
Alkylated piperazine compounds as inhibitors of btk activity
|
|
EP2592103A1
(en)
|
2011-11-08 |
2013-05-15 |
Adriacell S.p.A. |
Polymer aldehyde derivatives
|
|
AU2012340623A1
(en)
|
2011-11-23 |
2014-07-17 |
Igenica Biotherapeutics, Inc. |
Anti-CD98 antibodies and methods of use thereof
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
CN103204822B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
|
|
WO2013113102A1
(en)
|
2012-02-01 |
2013-08-08 |
The Governors Of The University Of Alberta |
USE OF PDGFR-α AS DIAGNOSTIC MARKER FOR PAPILLARY THYROID CANCER
|
|
WO2013169858A1
(en)
|
2012-05-08 |
2013-11-14 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
MX2014014831A
(es)
|
2012-06-08 |
2015-02-12 |
Hoffmann La Roche |
Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
|
|
WO2014001377A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
5-azaindazole compounds and methods of use
|
|
MX2015001399A
(es)
|
2012-08-02 |
2015-09-07 |
Genentech Inc |
Anticuerpos anti-etbr e inmunoconjugados.
|
|
MX2015001407A
(es)
|
2012-08-02 |
2015-05-08 |
Genentech Inc |
Inmunoconjugados y anticuerpos anti-etbr.
|
|
CN104780976B
(zh)
|
2012-08-13 |
2019-01-01 |
洛克菲勒大学 |
治疗和诊断黑素瘤
|
|
KR20150038068A
(ko)
|
2012-08-17 |
2015-04-08 |
에프. 호프만-라 로슈 아게 |
코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
|
|
WO2014033196A1
(en)
|
2012-08-30 |
2014-03-06 |
F. Hoffmann-La Roche Ag |
Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
|
|
KR102281288B1
(ko)
|
2012-09-26 |
2021-07-26 |
에프. 호프만-라 로슈 아게 |
환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
|
|
SG11201502757QA
(en)
|
2012-10-09 |
2015-05-28 |
Igenica Biotherapeutics Inc |
Anti-c16orf54 antibodies and methods of use thereof
|
|
NZ707486A
(en)
|
2012-10-12 |
2018-09-28 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine - anti-psma antibody conjugates
|
|
CA2941485C
(en)
|
2012-10-12 |
2018-06-12 |
Philip Wilson Howard |
Pyrrolobenzodiazepines and conjugates thereof
|
|
TR201808051T4
(tr)
|
2012-10-12 |
2018-06-21 |
Adc Therapeutics Sa |
Pirrolobenzodiazepin antikor konjugatları.
|
|
JP6392763B2
(ja)
|
2012-10-12 |
2018-09-19 |
エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ |
ピロロベンゾジアゼピン−抗体結合体
|
|
EP2906251B1
(en)
|
2012-10-12 |
2017-09-27 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
NZ706723A
(en)
|
2012-10-12 |
2018-07-27 |
Exelixis Inc |
Novel process for making compounds for use in the treatment of cancer
|
|
CA3060520C
(en)
|
2012-10-12 |
2022-05-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
ES2680153T3
(es)
|
2012-10-12 |
2018-09-04 |
Adc Therapeutics Sa |
Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
|
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
|
EP2920144A4
(en)
*
|
2012-11-15 |
2016-06-29 |
Univ Holy Ghost Duquesne |
CARBOXYLIC ACID TESTER PRODRUG HEMMER FROM MEK
|
|
TW201441193A
(zh)
*
|
2012-12-06 |
2014-11-01 |
Kyowa Hakko Kirin Co Ltd |
吡啶酮化合物
|
|
WO2014100755A2
(en)
|
2012-12-20 |
2014-06-26 |
Biomatrica, Inc. |
Formulations and methods for stabilizing pcr reagents
|
|
EA031585B1
(ru)
|
2012-12-21 |
2019-01-31 |
Медимьюн Лимитед |
Пирролобензодиазепины и их конъюгаты
|
|
WO2014096365A1
(en)
|
2012-12-21 |
2014-06-26 |
Spirogen Sàrl |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
|
RU2019109456A
(ru)
|
2013-02-22 |
2019-04-10 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
|
ES2703208T3
(es)
|
2013-02-27 |
2019-03-07 |
Daiichi Sankyo Co Ltd |
Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
|
|
US20160031887A1
(en)
|
2013-03-13 |
2016-02-04 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
MX364330B
(es)
|
2013-03-13 |
2019-04-23 |
Medimmune Ltd |
Pirrolobenzodiazepinas y conjugados de las mismas.
|
|
KR102057755B1
(ko)
|
2013-03-13 |
2019-12-19 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨쥬게이트
|
|
CN105246508A
(zh)
|
2013-03-14 |
2016-01-13 |
基因泰克公司 |
Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
|
|
DK2968346T3
(da)
|
2013-03-15 |
2024-05-06 |
Cancer Research Tech Llc |
Fremgangsmåder og sammensætninger til modulation af gamma-glutamylcyklus
|
|
EP2975936A4
(en)
|
2013-03-22 |
2017-03-15 |
University of Hawaii |
Novel stat3 inhibitors
|
|
EP3003390B1
(en)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
|
CA2915250A1
(en)
|
2013-06-13 |
2015-01-08 |
Biomatrica, Inc. |
Cell stabilization
|
|
CA2912359A1
(en)
|
2013-07-03 |
2015-01-08 |
F. Hoffmann-La Roche Ag |
Heteroaryl pyridone and aza-pyridone amide compounds
|
|
RU2016111131A
(ru)
|
2013-08-28 |
2017-10-03 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Способы конъюгации сайт-специфических антител и композиции
|
|
US9532987B2
(en)
|
2013-09-05 |
2017-01-03 |
Genentech, Inc. |
Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
|
|
RU2666141C2
(ru)
|
2013-09-17 |
2018-09-06 |
Оби Фарма, Инк. |
Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
|
WO2015052534A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
KR101813830B1
(ko)
|
2013-12-05 |
2017-12-29 |
에프. 호프만-라 로슈 아게 |
친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
|
|
EP3095462B1
(en)
|
2014-01-15 |
2019-08-14 |
Order-Made Medical Research Inc. |
Therapeutic pharmaceutical composition employing anti-slc6a6 antibody
|
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
|
MX2016012007A
(es)
|
2014-03-18 |
2016-12-05 |
Hoffmann La Roche |
Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso.
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
US10266603B2
(en)
|
2014-04-18 |
2019-04-23 |
The Governors Of The University Of Alberta |
Targeted therapy to restore radioactive iodine transport in thyroid cancer
|
|
AU2015249633B2
(en)
|
2014-04-25 |
2020-10-15 |
Genentech, Inc. |
Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
|
|
WO2015172073A1
(en)
|
2014-05-08 |
2015-11-12 |
Cornell University |
Bio-adhesive gels and methods of use
|
|
WO2015182734A1
(ja)
*
|
2014-05-30 |
2015-12-03 |
協和発酵キリン株式会社 |
含窒素複素環化合物
|
|
EP3942931A1
(en)
|
2014-06-10 |
2022-01-26 |
Biomatrica, INC. |
Stabilization of thrombocytes at ambient temperatures
|
|
CN106573060A
(zh)
|
2014-07-15 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
KR20170052600A
(ko)
|
2014-09-12 |
2017-05-12 |
제넨테크, 인크. |
시스테인 가공된 항체 및 콘주게이트
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
HUE052460T2
(hu)
|
2014-09-12 |
2021-04-28 |
Genentech Inc |
Anti-HER2 antitestek és immunkonjugátumok
|
|
MX2017003523A
(es)
|
2014-09-17 |
2017-11-08 |
Genentech Inc |
Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
|
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
JP6507234B2
(ja)
|
2014-10-02 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
|
|
US20170224670A1
(en)
|
2014-10-14 |
2017-08-10 |
Exelixis, Inc. |
Drug Combination to Treat Melanoma
|
|
MX379396B
(es)
|
2014-11-25 |
2025-03-11 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepina y anticuerpo.
|
|
DK3333191T3
(da)
|
2014-12-11 |
2020-10-26 |
Pf Medicament |
Anti-C10ORF54-antistoffer og anvendelser deraf
|
|
WO2016095088A1
(en)
*
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
WO2016095089A1
(en)
|
2014-12-15 |
2016-06-23 |
Merck Sharp & Dohme Corp. |
Erk inhibitors
|
|
CN112375077A
(zh)
|
2014-12-18 |
2021-02-19 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
WO2016164916A1
(en)
|
2015-04-10 |
2016-10-13 |
Thomas Jefferson University |
Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
|
|
GB201506389D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
DK3302551T3
(da)
|
2015-05-30 |
2024-08-26 |
Hoffmann La Roche |
Fremgangsmåder til behandling af HER2-positiv tidligere ubehandlet metastatisk brystkræft
|
|
WO2016205176A1
(en)
|
2015-06-15 |
2016-12-22 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
|
AR105483A1
(es)
*
|
2015-06-30 |
2017-10-11 |
Exelixis Inc |
Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
|
|
EP4272735B1
(en)
|
2015-06-30 |
2025-06-18 |
Genentech, Inc. |
Immediate-release tablets containing a drug and processes for forming the tablets
|
|
EP4585597A1
(en)
|
2015-07-02 |
2025-07-16 |
F. Hoffmann-La Roche AG |
Benzoxazepin oxazolidinone compounds and methods of use
|
|
CN111848643A
(zh)
|
2015-07-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
苯并氧氮杂*噁唑烷酮化合物及其使用方法
|
|
WO2017033113A1
(en)
|
2015-08-21 |
2017-03-02 |
Acerta Pharma B.V. |
Therapeutic combinations of a mek inhibitor and a btk inhibitor
|
|
WO2017041027A1
(en)
|
2015-09-04 |
2017-03-09 |
Obi Pharma, Inc. |
Glycan arrays and method of use
|
|
EP3370775B1
(en)
|
2015-11-03 |
2023-04-19 |
Genentech, Inc. |
Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
EP3377107B1
(en)
|
2015-11-19 |
2020-08-12 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
|
|
ES3037826T3
(en)
|
2015-12-08 |
2025-10-07 |
Biomatrica Inc |
Reduction of erythrocyte sedimentation rate
|
|
CN105330643B
(zh)
*
|
2015-12-09 |
2017-12-05 |
苏州明锐医药科技有限公司 |
卡比替尼的制备方法
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CN108367005B
(zh)
|
2016-02-29 |
2022-01-07 |
豪夫迈·罗氏有限公司 |
包含酪氨酸蛋白激酶抑制剂的剂型组合物
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
KR20250007056A
(ko)
|
2016-03-04 |
2025-01-13 |
다이호야쿠힌고교 가부시키가이샤 |
악성 종양 치료용 제제 및 조성물
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
JP2019513144A
(ja)
|
2016-03-29 |
2019-05-23 |
オービーアイ ファーマ，インコーポレイテッド |
抗体、医薬組成物及び方法
|
|
EP3443114A1
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
KR20250048399A
(ko)
|
2016-04-22 |
2025-04-08 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
CN106045969B
(zh)
*
|
2016-05-27 |
2019-04-12 |
湖南欧亚药业有限公司 |
一种卡比替尼的合成方法
|
|
EP3472162B1
(en)
|
2016-06-16 |
2021-11-17 |
F. Hoffmann-La Roche AG |
Heteroaryl estrogen receptor modulators and uses thereof
|
|
JP2019521983A
(ja)
|
2016-06-16 |
2019-08-08 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
|
|
AU2017302038B2
(en)
|
2016-07-27 |
2024-03-21 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
|
CN106220607B
(zh)
*
|
2016-07-27 |
2018-09-18 |
成都百事兴科技实业有限公司 |
一种s-3-(哌啶-2-基)-氮杂环丁烷-3-醇的合成方法
|
|
TWI786054B
(zh)
|
2016-07-29 |
2022-12-11 |
台灣浩鼎生技股份有限公司 |
人類抗體、醫藥組合物、及其方法
|
|
AU2017311585A1
(en)
|
2016-08-12 |
2019-02-28 |
Genentech, Inc. |
Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
|
|
TW201815419A
(zh)
|
2016-09-29 |
2018-05-01 |
美商建南德克公司 |
Mek抑制劑、 pd-1軸抑制劑及紫杉烷之組合療法
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
TWI822055B
(zh)
|
2016-11-21 |
2023-11-11 |
台灣浩鼎生技股份有限公司 |
共軛生物分子、醫藥組成物及方法
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2018146189A1
(en)
|
2017-02-08 |
2018-08-16 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
RS62343B1
(sr)
|
2017-02-08 |
2021-10-29 |
Adc Therapeutics Sa |
Pirolobenzodiazepin-antitelo konjugati
|
|
CN106866624B
(zh)
*
|
2017-02-27 |
2017-12-26 |
济宁医学院 |
一种卡比替尼的化学合成方法
|
|
US11994511B2
(en)
|
2017-04-04 |
2024-05-28 |
University Of Miami |
Biomarkers indicative of prostate cancer and treatment thereof
|
|
RS63502B1
(sr)
|
2017-04-18 |
2022-09-30 |
Medimmune Ltd |
Konjugati pirolobenzodiazepina
|
|
JP7402691B2
(ja)
|
2017-04-20 |
2023-12-21 |
アーデーセー セラピューティクス ソシエテ アノニム |
抗ｃｄ２５抗体薬物複合体による併用療法
|
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
AU2018285562B2
(en)
|
2017-06-14 |
2024-01-18 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
|
CA3064681A1
(en)
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-cd25 adc
|
|
HRP20220311T1
(hr)
|
2017-08-18 |
2022-05-13 |
Medimmune Limited |
Konjugati pirolobenzodiazepina
|
|
MX2020002553A
(es)
|
2017-09-08 |
2020-07-22 |
Hoffmann La Roche |
Metodos de diagnostico y terapeuticos para el cancer.
|
|
EP3752200A1
(en)
|
2018-02-13 |
2020-12-23 |
Vib Vzw |
Targeting minimal residual disease in cancer with rxr antagonists
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
SG11202008435SA
(en)
|
2018-03-19 |
2020-10-29 |
Taiho Pharmaceutical Co Ltd |
Pharmaceutical composition including sodium alkyl sulfate
|
|
JP2021518401A
(ja)
|
2018-03-21 |
2021-08-02 |
コロラド ステート ユニバーシティー リサーチ ファウンデーション |
がんワクチン組成物及びその使用方法
|
|
CN111902773B
(zh)
|
2018-03-26 |
2024-09-06 |
富士胶片株式会社 |
感光性树脂组合物及其制造方法、抗蚀剂膜、图案形成方法以及电子器件的制造方法
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
BR112020023846A2
(pt)
|
2018-05-23 |
2021-04-13 |
Adc Therapeutics Sa |
Adjuvante molecular
|
|
TW202504930A
(zh)
|
2018-06-27 |
2025-02-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
|
GB201811364D0
(en)
|
2018-07-11 |
2018-08-29 |
Adc Therapeutics Sa |
Combination therapy
|
|
US20230243836A1
(en)
|
2018-07-20 |
2023-08-03 |
Pierre Fabre Medicament |
Receptor for vista
|
|
CA3107085A1
(en)
|
2018-08-31 |
2020-03-05 |
Adc Therapeutics Sa |
Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax
|
|
JP2022504905A
(ja)
|
2018-10-16 |
2022-01-13 |
ノバルティス アーゲー |
標的化療法に対する応答を予測するためのバイオマーカーとしての単独の又は免疫マーカーと組み合わせた腫瘍突然変異負荷
|
|
CN113498340A
(zh)
*
|
2018-11-20 |
2021-10-12 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病噻吩基苯胺化合物
|
|
WO2020106306A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
JP7393808B2
(ja)
|
2018-11-20 |
2023-12-07 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのナフチリジノン－アニリン化合物
|
|
EP3883553A4
(en)
|
2018-11-20 |
2022-11-02 |
NFlection Therapeutics, Inc. |
ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CANCERS
|
|
WO2020109251A1
(en)
|
2018-11-29 |
2020-06-04 |
Adc Therapeutics Sa |
Dosage regime
|
|
GB201820725D0
(en)
|
2018-12-19 |
2019-01-30 |
Adc Therapeutics Sarl |
Pyrrolobenzodiazepine resistance
|
|
EP3899048A1
(en)
|
2018-12-19 |
2021-10-27 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine resistance
|
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
EP3938372B1
(en)
|
2019-03-15 |
2023-10-25 |
MedImmune Limited |
Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
|
|
WO2020187674A1
(en)
|
2019-03-15 |
2020-09-24 |
Sandoz Ag |
Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
|
|
CN114364798A
(zh)
|
2019-03-21 |
2022-04-15 |
欧恩科斯欧公司 |
用于治疗癌症的Dbait分子与激酶抑制剂的组合
|
|
LT3946464T
(lt)
|
2019-03-29 |
2022-11-10 |
Medimmune Limited |
Junginiai ir jų konjugatai
|
|
TWI735210B
(zh)
|
2019-04-26 |
2021-08-01 |
中國醫藥大學 |
Ａｄａｍ９抑制劑作為免疫調節劑之用途
|
|
GB201908128D0
(en)
|
2019-06-07 |
2019-07-24 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2020292965A1
(en)
|
2019-06-10 |
2022-01-27 |
Adc Therapeutics Sa |
Combination therapy comprising an anti-CD19 antibody drug conjugate and a PI3K inhibitor or a secondary agent
|
|
WO2020249527A1
(en)
|
2019-06-10 |
2020-12-17 |
Adc Therapeutics Sa |
Combination therapy comprising an anti-cd25 antibody drug conjugate and a further agent
|
|
SMT202400399T1
(it)
|
2019-07-22 |
2024-11-15 |
Lupin Ltd |
Composti macrociclici come agonisti di sting e metodi e usi di questi
|
|
GB201912059D0
(en)
|
2019-08-22 |
2019-10-09 |
Bergenbio As |
Combaination therapy of a patient subgroup
|
|
WO2021080608A1
(en)
|
2019-10-25 |
2021-04-29 |
Medimmune, Llc |
Branched moiety for use in conjugates
|
|
JP2023500906A
(ja)
|
2019-11-08 |
2023-01-11 |
インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） |
キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
|
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
|
US11174220B2
(en)
|
2019-12-13 |
2021-11-16 |
Inspirna, Inc. |
Metal salts and uses thereof
|
|
CN111170990B
(zh)
*
|
2020-01-16 |
2021-01-05 |
广州科锐特生物科技有限公司 |
一种3-哌啶-2-基-氮杂环丁烷-3-醇衍生物的制备方法
|
|
TW202140076A
(zh)
|
2020-01-22 |
2021-11-01 |
英商梅迪繆思有限公司 |
化合物及其軛合物
|
|
BR112022014391A2
(pt)
|
2020-01-22 |
2022-09-13 |
Medimmune Ltd |
Compostos e conjugados dos mesmos
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
GB202004189D0
(en)
|
2020-03-23 |
2020-05-06 |
Bergenbio As |
Combination therapy
|
|
EP4134081A4
(en)
|
2020-04-10 |
2024-05-01 |
Taiho Pharmaceutical Co., Ltd. |
Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor
|
|
US11701427B2
(en)
|
2020-04-16 |
2023-07-18 |
Regeneron Pharmaceuticals, Inc. |
Diels-alder conjugation methods
|
|
GB202006072D0
(en)
|
2020-04-24 |
2020-06-10 |
Bergenbio Asa |
Method of selecting patients for treatment with cmbination therapy
|
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
|
GB202012161D0
(en)
|
2020-08-05 |
2020-09-16 |
Adc Therapeutics Sa |
Combination therapy
|
|
IL300428A
(en)
|
2020-08-14 |
2023-04-01 |
Guangzhou Lupeng Pharmaceutical Company Ltd |
Dosage form compositions containing an inhibitor of BTK and its mutants
|
|
GB202015226D0
(en)
|
2020-09-25 |
2020-11-11 |
Adc Therapeutics S A |
Pyrrol obenzodiazepine-antibody conugates and uses thereof
|
|
GB202015916D0
(en)
|
2020-10-07 |
2020-11-18 |
Adc Therapeutics Sa |
Combination therapy
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
KR20230156731A
(ko)
|
2021-03-09 |
2023-11-14 |
제넨테크, 인크. |
뇌암 치료에 이용하기 위한 벨바라페닙
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
US20240366609A1
(en)
|
2021-04-06 |
2024-11-07 |
Genentech, Inc. |
Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab
|
|
JP2024521788A
(ja)
|
2021-05-27 |
2024-06-04 |
ミラティ セラピューティクス， インコーポレイテッド |
併用療法
|
|
GB202107709D0
(en)
|
2021-05-28 |
2021-07-14 |
Adc Therapeutics S A |
Combination therapy
|
|
GB202107713D0
(en)
|
2021-05-28 |
2021-07-14 |
Medimmune Ltd |
Combination therapy
|
|
GB202107706D0
(en)
|
2021-05-28 |
2021-07-14 |
Adc Therapeutics S A |
Combination therapy
|
|
KR102699226B1
(ko)
|
2021-06-09 |
2024-08-27 |
에프. 호프만-라 로슈 아게 |
암 치료를 위한 병용요법
|
|
WO2023274974A1
(en)
|
2021-06-29 |
2023-01-05 |
Adc Therapeutics Sa |
Combination therapy using antibody-drug conjugates
|
|
WO2023057545A1
(en)
|
2021-10-06 |
2023-04-13 |
Microquin Ltd. |
Substituted chalcones
|
|
AU2022383040A1
(en)
|
2021-11-04 |
2024-03-07 |
F. Hoffmann-La Roche Ag |
Novel use of quinazolinone compound for the treatment of cancer
|
|
KR20240125577A
(ko)
|
2021-11-23 |
2024-08-19 |
엔플렉션 테라퓨틱스, 인코포레이티드 |
피롤로피리딘-아닐린 화합물의 제형
|
|
CA3238209A1
(en)
|
2021-12-16 |
2023-06-22 |
Christian Kuhne |
Cell penetrating polypeptides (cpps) and their use in human therapy
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
CA3254594A1
(en)
*
|
2022-03-17 |
2023-09-21 |
SpringWorks Therapeutics Inc. |
PHENYLAMINO FLUORIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
|
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
|
GB202209285D0
(en)
|
2022-06-24 |
2022-08-10 |
Bergenbio Asa |
Dosage regimen for AXL inhibitor
|
|
WO2024033381A1
(en)
|
2022-08-10 |
2024-02-15 |
Vib Vzw |
Inhibition of tcf4/itf2 in the treatment of cancer
|
|
JP2025537786A
(ja)
|
2022-11-18 |
2025-11-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
進行性固形がんまたは転移の治療のためのｂｒａｆ阻害剤としてのキナゾリノン化合物
|
|
EP4406973A1
(en)
|
2023-01-27 |
2024-07-31 |
Fundació Privada Institut de Recerca de la SIDA-Caixa |
Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
|
|
WO2024209717A1
(ja)
|
2023-04-06 |
2024-10-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2025029650A1
(en)
|
2023-07-28 |
2025-02-06 |
Li Xiyan |
Nutritionally modified diets comprising aminoacids for use in treating a disease
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026019990A1
(en)
|
2024-07-18 |
2026-01-22 |
Genentech, Inc. |
Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies
|
|
WO2026024841A1
(en)
|
2024-07-24 |
2026-01-29 |
Astellas Us Llc |
Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
|